Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012 (2012), Article ID 650858, 4 pages
http://dx.doi.org/10.1100/2012/650858
Clinical Study

Prospective Study of Antibiotic Prophylaxis for Prostate Biopsy Involving >1100 Men

1Department of Urology, Adelaide and Meath Hospital, Tallaght, Dublin 24, Ireland
2Department of Microbiology, Adelaide and Meath Hospital, Tallaght, Dublin 24, Ireland

Received 11 October 2011; Accepted 21 December 2011

Academic Editors: K. M. Azadzoi and J. P. F. A. Heesakkers

Copyright © 2012 Rustom P. Manecksha et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, P. Autier, M. Boniol, M. Heanue, M. Colombet, and P. Boyle, “Estimates of the cancer incidence and mortality in Europe in 2006,” Annals of Oncology, vol. 18, no. 3, pp. 581–592, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. S. M. Collin, R. M. Martin, C. Metcalfe et al., “Prostate-cancer mortality in the USA and UK in 1975-2004: an ecological study,” The Lancet Oncology, vol. 9, no. 5, pp. 445–452, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Lange, C. Zappavigna, R. Hamidizadeh, S. L. Goldenberg, R. F. Paterson, and B. H. Chew, “Bacterial Sepsis After Prostate Biopsy-A New Perspective,” Urology, vol. 74, no. 6, pp. 1200–1205, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Matsumoto, H. Kiyota, M. Matsukawa, M. Yasuda, S. Arakawa, and K. Monden, “Japanese guidelines for prevention of perioperative infections in urological field,” International Journal of Urology, vol. 14, no. 10, pp. 890–909, 2007. View at Publisher · View at Google Scholar
  5. J. S. Wolf Jr, C. J. Bennett, R. R. Dmochowski, B. K. Hollenbeck, M. S. Pearle, and A. J. Schaeffer, “Best practice policy statement on urologic surgery antimicrobial prophylaxis,” Journal of Urology, vol. 179, no. 4, pp. 1379–1390, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Grabe, M. C. Bishop, and T. E. Bjerklund-Johansen, Guidelines on the management of urinary and male genital infections, 2009, http://www.uroweb.org/professional-resources/guidelines/online/?no_cache=1&view=archive.
  7. A. M. J. Bootsma, M. P. Laguna Pes, S. E. Geerlings, and A. Goossens, “Antibiotic Prophylaxis in Urologic Procedures: A Systematic Review,” European Urology, vol. 54, no. 6, pp. 1270–1286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. H. P. Burden, W. Ranasinghe, and R. Persad, “Antibiotics for transrectal ultrasonography-guided prostate biopsy: Are we practising evidence-based medicine?” British Journal of Urology International, vol. 101, no. 10, pp. 1202–1204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Aron, T. P. Rajeev, and N. P. Gupta, “Antibiotic prophylaxis for transrectal needle biopsy of the prostate: A randomized controlled study,” British Journal of Urology International, vol. 85, no. 6, pp. 682–685, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Kamdar, U. M. M. Mooppan, F. A. Gulmi, and H. Kim, “Multi-Drug-Resistant Bacteremia After Transrectal Ultrasound Guided Prostate Biopsies in Hospital Employees and Their Relatives,” Urology, vol. 72, no. 1, pp. 34–36, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Cam, A. Kayikci, Y. Akman, and A. Erol, “Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy,” International Journal of Urology, vol. 15, no. 11, pp. 997–1001, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Briffaux, P. Coloby, F. Bruyere et al., “One preoperative dose randomized against 3-day antibiotic prophylaxis for transrectal ultrasonography-guided prostate biopsy,” British Journal of Urology International, vol. 103, no. 8, pp. 1069–1073, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. D. C. Bean, D. Krahe, and D. W. Wareham, “Antimicrobial resistance in community and nosocomial Escerichia coli urinary tract isolates, London 2005-2006,” Annals of Clinical Microbiology and Antimicrobials, vol. 7, pp. 13–16, 2008. View at Publisher · View at Google Scholar
  14. A. P. Berger, C. Gozzi, H. Steiner et al., “Complication rate of transrectal ultrasound guided prostate biopsy: A comparison among 3 protocols with 6, 10 and 15 cores,” Journal of Urology, vol. 171, no. 4, pp. 1478–1480, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. L. Young, M. A. Liss, and R. J. Szabo, “Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy,” Urology, vol. 74, no. 2, pp. 332–338, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. J. Feliciano, E. Teper, M. Ferrandino et al., “The incidence of fluoroquinolone resistant infections after prostate biopsy-are fluoroquinolones still effective prophylaxis?” Journal of Urology, vol. 179, no. 3, pp. 952–955, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. H. M. Taylor and J. B. Bingham, “Antibiotic prophylaxis for transrectal prostate biopsy,” Journal of Antimicrobial Chemotherapy, vol. 39, no. 2, pp. 115–117, 1997. View at Publisher · View at Google Scholar · View at Scopus
  18. K. C. Shandera, G. P. Thibault, and G. E. Deshon, “Variability in patient preparation for prostate biopsy among American urologists,” Urology, vol. 52, no. 4, pp. 644–646, 1998. View at Publisher · View at Google Scholar · View at Scopus
  19. F.-J. Chen and H. J. Lo, “Molecular mechanisms of fluoroquinolone resistance,” Journal of Microbiology, Immunology and Infection, vol. 36, no. 1, pp. 1–9, 2003. View at Google Scholar · View at Scopus
  20. L. B. Boyd, R. L. Atmar, G. L. Randall, R. J. Hamill, D. Steffen, and L. Zechiedrich, “Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location,” BMC Infectious Diseases, vol. 8, p. 4, 2008. View at Publisher · View at Google Scholar
  21. B. Chappell and T. O'Brien, “Infections after prostate biopsy and antibiotic resistance,” British Journal of Urology International, vol. 103, no. 3, p. 409, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. K. H. Yuk, C. H. Nightingale, R. Quintiliani, and K. R. Sweeney, “Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers,” Antimicrobial Agents and Chemotherapy, vol. 35, no. 2, pp. 384–386, 1991. View at Google Scholar · View at Scopus
  23. J. A. Dromigny, P. Nabeth, A. Juergens-Behr, and J. D. Perrier-Gros-Claude, “Risk factors for antibiotic-resistant Escherichia coli isolated from community-acquired urinary tract infections in Dakar, Senegal,” Journal of Antimicrobial Chemotherapy, vol. 56, no. 1, pp. 236–239, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. E. Ozden, Y. Bostanci, K. Y. Yakupoglu et al., “Incidence of acute prostatitis caused by extended-spectrum β-lactamase-producing Escherichia coli after transrectal prostate biopsy,” Urology, vol. 74, no. 1, pp. 119–123, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Batura, G. G. Rao, and P. B. Nielsen, “Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy,” British Journal of Urology International, vol. 106, no. 7, pp. 1017–1020, 2010. View at Publisher · View at Google Scholar · View at Scopus